皮疹
医学
耐受性
药代动力学
不利影响
内科学
肿瘤科
头颈部
基底细胞
头颈部癌
单克隆抗体
外科
癌症
抗体
免疫学
作者
Lars Bastholt,Lena Specht,Kenneth Jensen,Eva Brun,Annika Loft,Jørgen Petersen,Helle Kastberg,Jesper Grau Eriksen
标识
DOI:10.1016/j.radonc.2007.06.007
摘要
To assess safety, tolerability, pharmacokinetics and clinical activity of HuMax-EGFr in patients with SCCHN.Twenty-eight patients with SCCHN were enrolled. The study comprised a single-dose escalation part for assessment of safety issues followed by a repeat dose extension including 4 weekly infusions at the same doses. Efficacy and metabolic response were evaluated according to RECIST by CT and FDG-PET.Most frequently reported adverse event was rash. All but one event were CTC grade 1 or 2 and a dose-dependent relationship was indicated. Duration of skin reactions varied from few days to 2 months. No DLTs were observed and MTD was not reached. In the two highest dose groups, 7 of 11 patients obtained a PR or SD and 9 patients obtained metabolic PR or SD.HuMax-EGFr can be safely administered in doses up to 8 mg/kg, and preliminary data on tumour response are encouraging.
科研通智能强力驱动
Strongly Powered by AbleSci AI